spevatamig

Spevatamig (PT886) is a first-in-class IgG1-based bispecific antibody developed by Phanes Therapeutics that simultaneously targets Claudin 18.2 (CLDN18.2) and CD47. It is engineered with a native IgG structure using Phanes' proprietary PACbody and SPECpair platforms. The molecule features a single anti-CLDN18.2 arm to reduce binding to gastric mucosa, thereby mitigating the nausea and vomiting typically associated with CLDN18.2-targeted therapies. Additionally, it contains an optimized anti-CD47 arm with higher affinity for cancer cells than for human red blood cells, which helps prevent hematological toxicities like anemia and thrombocytopenia. Spevatamig is currently in Phase 1/2 clinical development (the TWINPEAK study) for advanced gastrointestinal cancers, including pancreatic ductal adenocarcinoma (PDAC), gastric, gastroesophageal junction (GEJ), and biliary tract adenocarcinomas. It is being evaluated as a monotherapy and in combination with chemotherapy (gemcitabine and nab-paclitaxel) or the anti-PD-1 therapy pembrolizumab.

Other names

spevatamig